The abuse potential of two novel synthetic cathinones with modification on the alpha-carbon position, 2-cyclohexyl-2-(methylamino)-1-phenylethanone (MACHP) and 2-(methylamino)-1-phenyloctan-1-one (MAOP), and their effects on dopaminergic activity

Pharmacology Biochemistry and Behavior

Volumn 153, Issue , 2017, Pages 160-167

  Botanas, Chrislean Jun ^a   Yoon, Seong Shoon ^b   de la Peña, June Bryan ^a   dela Peña, Irene Joy ^a   Kim, Mikyung ^a   Woo, Taeseon ^a   Seo, Joung Wook ^b   Jang, Choon Gon ^c   Park, Kyung Tae ^d   Lee, Young Hun ^d   Lee, Yong Sup ^d   Kim, Hee Jin ^a   Cheong, Jae Hoon ^a  

^a Sahmyook University   (South Korea)

^b Korea Institute of Toxicology   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d Kyung Hee University   (South Korea)

Author keywords

Abuse potential; Conditioned place preference; Locomotor sensitization; Self administration; Synthetic cathinones

Indexed keywords

2 (METHYLAMINO) 1 PHENYLOCTAN 1 ONE; 2 CYCLOHEXYL 2 (METHYLAMINO) 1 PHENYLETHANONE; CATHINONE; UNCLASSIFIED DRUG; ALKALOID; DOPAMINE TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONDITIONED PLACE PREFERENCE TEST; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; GENE EXPRESSION; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SELF ADMINISTRATION TEST; ANIMAL; CONDITIONING; DOPAMINERGIC NERVE CELL; DRUG DEPENDENCE; DRUG EFFECTS; DRUG SELF ADMINISTRATION; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE; MOTOR ACTIVITY; REWARD; SPRAGUE DAWLEY RAT;

ALKALOIDS; ANIMALS; CONDITIONING (PSYCHOLOGY); DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; MALE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; REWARD; SELF ADMINISTRATION; SUBSTANCE-RELATED DISORDERS;

EID: 85008640778     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2016.12.017     Document Type: Article

References (38)

1. Aarde, S.M., Angrish, D., Barlow, D.J., Wright, M.J. Jr., Vandewater, S.A., Creehan, K.M., Houseknecht, K.L., Dickerson, T.J., Taffe, M.A., Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats. Addict. Biol. 18:5 (2013), 786–799.
2. Abiedalla, Y.F.H., Abdel-Hay, K., DeRuiter, J., Clark, C.R., Synthesis and GC–MS analysis of a series of homologs and regioisomers of 3, 4-methylenedioxypyrovalerone (MDPV). Forensic Sci. Int. 223:1 (2012), 189–197.
3. Banks, M.L., Worst, T.J., Rusyniak, D.E., Sprague, J.E., Synthetic cathinones (“bath salts”). J. Emerg. Med. 46:5 (2014), 632–642.
4. Berquist, M.D., Traxler, H.K., Mahler, A.M., Baker, L.E., Sensitization to the locomotor stimulant effects of “bath salt” constituents, 4-methylmethcathinone (4-MMC) and 3, 4-methylenedioxypyrovalerone (MDPV), in male Sprague-Dawley rats. Drug Alcohol Depend. 164 (2016), 128–134.
5. Blough, B.E., Landavazo, A., Partilla, J.S., Baumann, M.H., Decker, A.M., Page, K.M., Rothman, R.B., Hybrid dopamine uptake blocker–serotonin releaser ligands: a new twist on transporter-focused therapeutics. ACS Med. Chem. Lett. 5:6 (2014), 623–627.
6. Brandt, S.D., Freeman, S., Sumnall, H.R., Measham, F., Cole, J., Analysis of NRG ‘legal highs’ in the UK: identification and formation of novel cathinones. Drug Test. Anal. 3:9 (2011), 569–575.
7. Carroll, F.I., Blough, B.E., Abraham, P., Mills, A.C., Holleman, J.A., Wolckenhauer, S.A., Decker, A.M., Landavazo, A., McElroy, K.T., Navarro, H.A., Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J. Med. Chem. 52:21 (2009), 6768–6781.
8. Coppola, M., Mondola, R., Synthetic cathinones: chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as “bath salts” or “plant food”. Toxicol. Lett. 211:2 (2012), 144–149.
9. de la Peña, J.B.I., Lee, H.C., Ike, C., Woo, T.S., Yoon, S.Y., Lee, H.L., Han, J.S., Lee, J.I., Cho, Y.J., Shin, C.Y., Rewarding and reinforcing effects of the NMDA receptor antagonist–benzodiazepine combination, zoletil®: difference between acute and repeated exposure. Behav. Brain Res. 233:2 (2012), 434–442.
10. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Perspectives On Drugs: Injection of Synthetic Cathinones. 2015 (Europe http://www.emcdda.europa.eu/topics/pods/synthetic-cathinones-injection. Accessed on September 25, 2016).
11. Everitt, B.J., Robbins, T.W., From the ventral to the dorsal striatum: devolving views of their roles in drug addiction. Neurosci. Biobehav. Rev. 37:9 (2013), 1946–1954.
12. Gatch, M.B., Dolan, S.B., Forster, M.J., Comparative behavioral pharmacology of three pyrrolidine-containing synthetic cathinone derivatives. J. Pharmacol. Exp. Ther. 354:2 (2015), 103–110.
13. German, C.L., Fleckenstein, A.E., Hanson, G.R., Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sci. 97:1 (2014), 2–8.
14. Goldstein, R.Z., Volkow, N.D., Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am. J. Psychiatr., 2002.
15. Gregg, R.A., Tallarida, C.S., Reitz, A., McCurdy, C., Rawls, S.M., Mephedrone (4-methylmethcathinone), a principal constituent of psychoactive bath salts, produces behavioral sensitization in rats. Drug Alcohol Depend. 133:2 (2013), 746–750.
16. Hwang, J.Y., Kim, J.S., Oh, J.H., Hong, S.I., Ma, S.X., Jung, Y.H., Ko, Y.H., Lee, S.Y., Kim, H.C., Jang, C.G., The new stimulant designer compound pentedrone exhibits rewarding properties and affects dopaminergic activity. Addict. Biol., 2015.
17. Karila, L., Megarbane, B., Cottencin, O., Lejoyeux, M., Synthetic cathinones: a new public health problem. Curr. Neuropharmacol. 13:1 (2015), 12–20.
18. Karlsson, L., Andersson, M., Kronstrand, R., Kugelberg, F.C., Mephedrone, Methylone and 3, 4-methylenedioxypyrovalerone (MDPV) induce conditioned place preference in mice. Basic Clin. Pharmacol. Toxicol. 115:5 (2014), 411–416.
19. Koob, G.F., Le Moal, M., Neurobiology of drug addiction. Stages and Pathways of Drug Involvement: Examining the Gateway Hypothesis, 2002, Cambridge University Press, New York, 337–361.
20. Lisek, R., Xu, W., Yuvasheva, E., Chiu, Y.-T., Reitz, A.B., Liu-Chen, L.-Y., Rawls, S.M., Mephedrone (‘bath salt’) elicits conditioned place preference and dopamine-sensitive motor activation. Drug Alcohol Depend. 126:1 (2012), 257–262.
21. Maheux, C.R., Copeland, C.R., Chemical analysis of two new designer drugs: buphedrone and pentedrone. Drug Test. Anal. 4:1 (2012), 17–23.
22. Marusich, J.A., Grant, K.R., Blough, B.E., Wiley, J.L., Effects of synthetic cathinones contained in “bath salts” on motor behavior and a functional observational battery in mice. Neurotoxicology 33:5 (2012), 1305–1313.
23. Metzger, R.R., Haughey, H.M., Wilkins, D.G., Gibb, J.W., Hanson, G.R., Fleckenstein, A.E., Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia. J. Pharmacol. Exp. Ther. 295:3 (2000), 1077–1085.
24. Motbey, C.P., Clemens, K.J., Apetz, N., Winstock, A.R., Ramsey, J., Li, K.M., Wyatt, N., Callaghan, P.D., Bowen, M.T., Cornish, J.L., High levels of intravenous mephedrone (4-methylmethcathinone) self-administration in rats: neural consequences and comparison with methamphetamine. J. Psychopharmacol. 27:9 (2013), 823–836.
25. Oh, J.H., Hwang, J.Y., Hong, S.I., Ma, S.X., Seo, J.Y., Lee, S.Y., Kim, H.C., Jang, C.G., The new designer drug buphedrone produces rewarding properties via dopamine D1 receptor activation. Addict. Biol., 2016.
26. Paillet-Loilier, M., Cesbron, A., Le Boisselier, R., Bourgine, J., Debruyne, D., Emerging drugs of abuse: current perspectives on substituted cathinones. Substance Abuse and Rehabilitation, 5, 2014, 37.
27. Piazza, P.V., Le Moal, M., The role of stress in drug self-administration. Trends Pharmacol. Sci. 19:2 (1998), 67–74.
28. Pierce, R.C., Kalivas, P.W., A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res. Rev. 25:2 (1997), 192–216.
29. Power, J.D., McGlynn, P., Clarke, K., McDermott, S.D., Kavanagh, P., O'Brien, J., The analysis of substituted cathinones. Part 1: chemical analysis of 2-, 3-and 4-methylmethcathinone. Forensic Sci. Int. 212:1 (2011), 6–12.
30. Prosser, J.M., Nelson, L.S., The toxicology of bath salts: a review of synthetic cathinones. J. Med. Toxicol. 8:1 (2012), 33–42.
31. Spiller, H.A., Ryan, M.L., Weston, R.G., Jansen, J., Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clin. Toxicol. 49:6 (2011), 499–505.
32. Steketee, J.D., Kalivas, P.W., Drug wanting: behavioral sensitization and relapse to drug-seeking behavior. Pharmacol. Rev. 63:2 (2011), 348–365.
33. Ujike, H., Akiyama, K., Otsuki, S., D-2 but not D-1 dopamine agonists produce augmented behavioral response in rats after subchronic treatment with methamphetamine or cocaine. Psychopharmacology 102:4 (1990), 459–464.
34. VanGuilder, H.D., Vrana, K.E., Freeman, W.M., Twenty-five years of quantitative PCR for gene expression analysis., 44(5), 2008, 619.
35. Watterson, L.R., Olive, M.F., Synthetic cathinones and their rewarding and reinforcing effects in rodents. Adv. Neuroimmunol., 2014, 2014.
36. Xu, P., Qiu, Y., Zhang, Y., Βai, Y., Liu, Y., Kim, J., Shen, H., The effects of 4-methylethcathinone on conditioned place preference. Locomotor Sensitization, and Anxiety-Like Behavior: A Comparison with Methamphetamine, 2015 (The international journal of neuropsychopharmacology/official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)).
37. Zhu, J., Reith, M., Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse. CNS Neurol. Disord. Drug Targets 7:5 (2008), 393–409.
38. Zuba, D., Adamowicz, P., Byrska, B., Detection of buphedrone in biological and non-biological material–two case reports. Forensic Sci. Int. 227:1 (2013), 15–20.